Loading company…
Pulmatrix develops inhaled therapeutics for respiratory diseases using its iSPERSE™ technology.
Founded in 2003, Pulmatrix develops pulmonary-delivered therapies using its iSPERSE™ technology, which is designed to deliver medication to the lungs. Its work targets respiratory conditions including asthma and chronic obstructive pulmonary disease. CEO Ted Raad leads the company. Pulmatrix raised USD 19.2 million in an IPO in March 2014 and USD 15.2 million through funding efforts including a March 2018 private placement.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in